Chronic granulocytic leukemia is mostly assessed by the 10-year survival rate to assess the prognosis, up to live 20 years this statement is too absolute, clinically after active treatment, some patients can survive more than 20 years, there is no absolute survival period. Chronic granulocytic leukemia is a malignant tumor formed by clonal proliferation of bone marrow hematopoietic stem cells. In recent years, tyrosine kinase inhibitors (TKIs) represented by imatinib as the first-line therapeutic drugs have resulted in a 10-year survival rate of 85% to 90% for patients with chronic granulocytic leukemia. Patients who have sustained and stable deep molecular remission for more than 2 years after TKI treatment are partly able to obtain long-term treatment-free remission (TFR), i.e., functional cure, and the survival of this group of patients is significantly improved, and can be more than 20 years if they do not relapse. With the development of medical technology, the functional cure rate is getting higher and higher, and the prognosis of patients has been improved. Patients with chronic granulomas can prolong their lives through active treatment and correct confrontation under the guidance of physicians. If there is any discomfort, it is recommended to consult a doctor in time.